RecruitingPhase 1Phase 2NCT04006808

A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

A Reactogenicity, Safety and Immunogenicity Study of GSK's Paediatric Herpes Zoster Subunit Candidate Vaccine (PED-HZ/su) GSK143713A in Immunocompromised Paediatric Renal Transplant Recipients

Sponsor

GlaxoSmithKline

Enrollment

184 participants

Start Date

Oct 25, 2019

Study Type

INTERVENTIONAL

Conditions

Herpes Zoster

Summary

The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant recipients aged 1-17 years

Eligibility

Min Age: 1 YearMax Age: 17 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called PED-HZ/su for people with herpes zoster. The study is currently recruiting participants at 31 locations. People eligible for this study include aged 1 Year to 17 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALPED-HZ/su

GSK's candidate vaccine- PED-HZ/su. is administered intramuscularly in the deltoid of the non-dominant arm, on a two-dose schedule in the two investigational groups.

Locations(31)

GSK Investigational Site

Brussels, Belgium

GSK Investigational Site

Ghent, Belgium

GSK Investigational Site

Leuven, Belgium

GSK Investigational Site

Liège, Belgium

GSK Investigational Site

Bordeaux, France

GSK Investigational Site

Lille, France

GSK Investigational Site

Marseille, France

GSK Investigational Site

Montpellier, France

GSK Investigational Site

Nantes, France

GSK Investigational Site

Paris, France

GSK Investigational Site

Paris, France

GSK Investigational Site

Toulouse, France

GSK Investigational Site

Genova, Italy

GSK Investigational Site

Milan, Italy

GSK Investigational Site

Padova, Italy

GSK Investigational Site

Roma, Italy

GSK Investigational Site

Torino, Italy

GSK Investigational Site

Gdansk, Poland

GSK Investigational Site

BaracaldoVizcaya, Spain

GSK Investigational Site

Espluges de Llobregat, Spain

GSK Investigational Site

HebrOn, Spain

GSK Investigational Site

Madrid, Spain

GSK Investigational Site

Madrid, Spain

GSK Investigational Site

Seville, Spain

GSK Investigational Site

Birmingham, United Kingdom

GSK Investigational Site

Cardiff, United Kingdom

GSK Investigational Site

Glasgow Strathclyde, United Kingdom

GSK Investigational Site

London, United Kingdom

GSK Investigational Site

Manchester, United Kingdom

GSK Investigational Site

Nottingham, United Kingdom

GSK Investigational Site

Southampton, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04006808

Related Trials

The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster

NCT073617961 location

Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

NCT055804581 location

A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

NCT075025608 locations

Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine

NCT075853701 location

The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster

NCT073071701 location